Relatlimab

• A phase 2 trial in stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab - TURANDORELA Recruiting
  2023-507460-39-00 Phase II/III 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• Pan tumor Roll Over Study Recruiting
  2023-506914-32-00 Phase II 10 countries Bristol-Myers Squibb Services Unlimited Company
• Pre-operative phase II trial for breast cancer with nivolumab in combination with novel IO (BELLINI trial) Recruiting
  2024-515080-54-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• Neoadjuvant immune checkpoint inhibition and novel IO combinations in early-stage colon cancer - the NICHE trial Recruiting
  2024-513314-35-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• Prospective, randomized, neoadjuvant phase II study with combination immuno-oncology in primary clear cell renal cell cancer at risk for rec… Ended
  2024-515514-40-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• A Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy in Participants with St… Ended
  2023-508372-10-00 Phase II 9 countries Bristol-Myers Squibb Services Unlimited Company
• Relatlimab + Nivolumab in Pediatric and Young Adult Lymphomas (RELATIVITY-069) Ended
  2023-503715-14-00 Phase I/II 4 countries Bristol Myers Squibb International Corporation
• Phase 1/2 study of Nivolumab and Relatlimab in Combination with Bevacizumab in First-line HCC Ended
  2024-510649-33-00 Phase I/II 5 countries Bristol Myers Squibb International Corporation
• An Open-Label Phase I/II Study of Relatlimab (BMS-986016) with Nivolumab (BMS-936558) in Combination with 5-Azacytidine for Relapsed/Refract… Ended
  2024-514948-89-00 Phase I/II 1 country Klinikum der Universitaet Muenchen AöR
• A Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Liver Cancer who have never been been Treated with Immuno-… Ended
  2023-503519-13-00 Phase II 5 countries Bristol Myers Squibb International Corporation
• CONGRATS : COMBINATION OF NIVOLUMAB PLUS RELATLIMAB IN PATIENTS WITH ADVANCED OR METASTATIC SOFT-TISSUE SARCOMA: A PROOF-OF-CONCEPT RANDOMIZ… Ended
  2023-509495-42-00 Phase II 1 country Institut Bergonie
• Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinant… Ended
  2024-513074-22-00 Phase II 3 countries Universitaetsklinikum Essen AöR
• An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread Ended
  2023-508207-21-00 Phase I/II 3 countries Bristol Myers Squibb International Corporation
• Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Ended
  2023-508067-70-00 Phase I/II 9 countries Bristol Myers Squibb International Corporation
• A Study of Nivolumab and Nivolumab Combinations in Recurrent and Metastatic Colon Cancer Ended
  2024-516004-42-01 Phase II 2 countries Bristol Myers Squibb International Corporation

Showing 1–15 of 15 trials